帕博利珠单抗联合化疗改善转移性鳞状NSCLC患者健康相关生活质量:KEYNOTE-407患者报告结局
KEYNOTE-407研究评估帕博利珠单抗联合卡铂-紫杉醇/白蛋白紫杉醇对比安慰剂联合化疗一线治疗转移性鳞状NSCLC的患者报告结局。共554例和553例患者分别完成至少一次QLQ-C30或QLQ-LC13评估。联合组全球健康状况/生活质量评分在第9周和第18周较基线改善,而安慰剂组恶化,组间差异有统计学意义;
要点
- 帕博利珠单抗联合化疗组第9周和第18周全球健康状况/生活质量评分较基线改善,安慰剂组恶化。
核心结论
- 在化疗基础上加用帕博利珠单抗可维持或改善转移性鳞状NSCLC患者的健康相关生活质量,并在第9周和第18周优于单纯化疗。
研究设计与样本
- KEYNOTE-407为3期随机对照研究,患者随机接受4周期帕博利珠单抗200 mg或安慰剂每3周一次联合卡铂+紫杉醇或白蛋白紫杉醇,后续帕博利珠单抗或安慰剂最多31周期。
- 健康相关生活质量采用EORTC QLQ-C30和QLQ-LC13评估,共554例和553例患者分别完成至少一次QLQ-C30或QLQ-LC13评估。
主要发现
- 帕博利珠单抗联合组QLQ-C30全球健康状况/生活质量评分较基线变化:第9周最小二乘均值1.8(95%CI -0.9至4.4),第18周4.3(95%CI 1.7至6.9)。
- 安慰剂联合组QLQ-C30全球健康状况/生活质量评分较基线变化:第9周-1.8(95%CI -4.4至0.7),第18周-0.57(95%CI -3.3至2.2)。
临床怎么用
- 对于既往未治疗的转移性鳞状NSCLC患者,帕博利珠单抗联合卡铂-紫杉醇/白蛋白紫杉醇一线治疗可维持或改善健康相关生活质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In the phase 3 KEYNOTE-407 study, the addition of pembrolizumab to carboplatin-paclitaxel/nab-paclitaxel significantly improved overall survival, progression-free survival, and objective response rate in patients with previously untreated metastatic squamous non-small-cell lung cancer (NSCLC), with little impact on severe toxicity. We present patient-reported outcomes (PROs) from KEYNOTE-407. METHODS: Patients were randomly assigned to receive 4 cycles of pembrolizumab 200 mg or placebo once every 3 weeks plus carboplatin plus paclitaxel or nab-paclitaxel, followed by pembrolizumab or placebo for an additional 31 cycles. Health-related quality of life (HRQoL) was evaluated using the European Organisation for Research and Treatment of Cancer Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30) and Quality of Life Questionnaire-Lung Cancer Module 13 (QLQ-LC13). Key PRO endpoints were change from baseline to weeks 9 and 18 (during and after platinum therapy) in the QLQ-C30 global health status/quality of life (GHS/QoL) score and time to deterioration in the composite endpoint of cough, chest pain, or dyspnea from the QLQ-C30 and QLQ-LC13. Two-sided, nominal P values are provided. RESULTS: A total of 554 and 553 patients completed ≥ 1 QLQ-C30 or ≥ 1 QLQ-LC13 assessment, respectively. GHS/QoL score improved for the pembrolizumab-combination group (least squares [LS] mean [95% CI] change from baseline: week 9, 1.8 [-0.9 to 4.4]; week 18, 4.3 [1.7 to 6.9]) and deteriorated in the placebo-combination group (week 9, -1.8 [-4.4 to 0.7]; week 18, -0.57 [-3.3 to 2.2]). Between-group differences were improved for the pembrolizumab-combination group (difference in LS mean scores: week 9, 3.6 [95% CI, 0.3 to 6.9], nominal P = .0337; week 18, 4.9 [1.4 to 8.3], nominal P = .0060). Median time to deterioration in cough, chest pain, or dyspnea was not reached in either group (hazard ratio, 0.79; 95% CI, 0.58 to 1.06]; nominal P = .125). CONCLUSION: Addition of pembrolizumab to chemotherapy maintained or improved HRQoL measurements relative to baseline and improved HRQoL versus chemotherapy alone at weeks 9 and 18. These results support use of pembrolizumab plus chemotherapy as first-line therapy for metastatic squamous NSCLC.
引用
- Mazieres J, Kowalski D, Luft A, et al. Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2019. PMID: 31751163. doi:10.1200/JCO.19.01348
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。